Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis LtdfiledCriticalDomantis Ltd
Publication of DOP2009000265ApublicationCriticalpatent/DOP2009000265A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La invención se relaciona con dominios variables simples (dAb) de polipeptidos y anticuerpos del anti-TNFR1 que son resistentes a la degradacion por una proteasa, asi como a los antagonistas que comprende estos. Los polipeptidos, dAb y antagonistas son utiles como terapeuticos y/o profilacticos probablemente para combatir las proteasas cuando se administran a un paciente, por ejemplo por administracion pulmonar, administracion oral, suministro al pulmon y suministro al tracto GI de un paciente, asi como para tratar enfermedades inflamatorias, tal como artritis o COPD.The invention relates to simple variable domains (dAb) of anti-TNFR1 polypeptides and antibodies that are resistant to degradation by a protease, as well as to the antagonists comprising these. Polypeptides, dAb and antagonists are useful as therapeutic and / or prophylactic to probably combat proteases when administered to a patient, for example by pulmonary administration, oral administration, lung delivery and supply to a patient's GI tract, as well as to treat inflammatory diseases, such as arthritis or COPD.
DO2009000265A2007-06-062009-11-27
POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
DOP2009000265A
(en)
Compounds derived from heterocycles, antagonists for ccr2; and use of the compounds to treat respiratory tract conditions or diseases, such as chronic obstructive pulmonary disease and asthma.
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition.